Why the study?
Do low molecular weight heparins (particularly enoxaparin) prevent deep vein thrombosis in patients after surgery?
Do low molecular weight heparins (particularly enoxaparin) prevent deep vein thrombosis in patients after surgery?
Enoxaparin and other LMWHs are effective, safe, and cost-effective for thromboprophylaxis in moderate to high-risk surgical patients.
Supports LMWH thromboprophylaxis in moderate/high-risk surgical patients; leaves open confirmation by contemporary RCTs.
This review discusses the problem of deep vein thrombosis (DVT) after operation and identifies three levels of risk of DVT: low (less than 10 per cent), moderate (10-40 per cent) and high (40-80 per cent). Special emphasis is placed on the most recent prophylactic treatment, low molecular weight heparins (LMWHs), particularly enoxaparin. Several LMWHs are now available, but they differ slightly and each must be evaluated on its own merits. In general, however, LMWHs are both effective and safe in those patients at moderate or high risk of DVT. Thromboprophylaxis is cost effective when analysed using health-economic methodology.
No takes yet. Share an insight, caveat, or question.
Bergqvist et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: